1
|
Singh M, Ingle A, González A, Mariathomas P, Ramanathan R, Taylor PD, Christofferson AJ, Spencer MJS, Low MX, Ahmed T, Walia S, Trasobares S, Manzorro R, Calvino JJ, García-Fernández E, Orte A, Dominguez-Vera JM, Bansal V. Repairing and Preventing Photooxidation of Few-Layer Black Phosphorus with β-Carotene. ACS Nano 2023; 17:8083-8097. [PMID: 37093765 DOI: 10.1021/acsnano.2c10232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Few-layer black phosphorus (FLBP), a technologically important 2D material, faces a major hurdle to consumer applications: spontaneous degradation under ambient conditions. Blocking the direct exposure of FLBP to the environment has remained the key strategy to enhance its stability, but this can also limit its utility. In this paper, a more ambitious approach to handling FLBP is reported where not only is FLBP oxidation blocked, but it is also repaired postoxidation. Our approach, inspired by nature, employs the antioxidant molecule β-carotene that protects plants against photooxidative damages to act as a protecting and repairing agent for FLBP. The mechanistic role of β-carotene is established by a suite of spectro-microscopy techniques, in combination with computational studies and biochemical assays. Transconductance studies on FLBP-based field effect transistor (FET) devices further affirm the protective and reparative effects of β-carotene. The outcomes indicate the potential for deploying a plethora of natural antioxidant molecules to enhance the stability of other environmentally sensitive inorganic nanomaterials and expedite their translation for technological and consumer applications.
Collapse
Affiliation(s)
- Mandeep Singh
- Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, RMIT University, Melbourne, Victoria 3000, Australia
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | - Aviraj Ingle
- Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, RMIT University, Melbourne, Victoria 3000, Australia
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | - Ana González
- Departamento de Química Inorgánica and Instituto de Biotecnología. Unidad de Excelencia de Química aplicada a Biomedicina y Medioambiente, Universidad de Granada, 18071 Granada, Spain
| | - Pyria Mariathomas
- Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, RMIT University, Melbourne, Victoria 3000, Australia
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | - Rajesh Ramanathan
- Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, RMIT University, Melbourne, Victoria 3000, Australia
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | - Patrick D Taylor
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | | | - Michelle J S Spencer
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
- ARC Centre of Excellence in Future Low-Energy Electronics Technologies (FLEET), RMIT University, Melbourne, Victoria 3000, Australia
| | - Mei Xian Low
- School of Engineering, RMIT University, Melbourne, Victoria 3000, Australia
| | - Taimur Ahmed
- School of Engineering, RMIT University, Melbourne, Victoria 3000, Australia
| | - Sumeet Walia
- School of Engineering, RMIT University, Melbourne, Victoria 3000, Australia
| | - Susana Trasobares
- Departamento Ciencia de Materiales e Ingeniería Metalúrgicay Química Inorgánica, Universidad de Cádiz, 11510 Cádiz, Spain
| | - Ramón Manzorro
- Departamento Ciencia de Materiales e Ingeniería Metalúrgicay Química Inorgánica, Universidad de Cádiz, 11510 Cádiz, Spain
| | - Jose J Calvino
- Departamento Ciencia de Materiales e Ingeniería Metalúrgicay Química Inorgánica, Universidad de Cádiz, 11510 Cádiz, Spain
| | - Emilio García-Fernández
- Nanoscopy-UGR Lab. Departamento de Fisicoquímica. Unidad de Excelencia de Química aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, 18071 Granada, Spain
| | - Angel Orte
- Nanoscopy-UGR Lab. Departamento de Fisicoquímica. Unidad de Excelencia de Química aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, 18071 Granada, Spain
| | - Jose M Dominguez-Vera
- Departamento de Química Inorgánica and Instituto de Biotecnología. Unidad de Excelencia de Química aplicada a Biomedicina y Medioambiente, Universidad de Granada, 18071 Granada, Spain
| | - Vipul Bansal
- Ian Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, RMIT University, Melbourne, Victoria 3000, Australia
- School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| |
Collapse
|
2
|
Fernández-Díaz C, Castañeda S, Melero R, Loricera J, Ortiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, Rodriguéz-Muguruza S, Rodrigez-Garcia S, Castellanos-Moreira R, Almodovar R, Aguilera Cros C, Villa-Blanco I, Ordoñez S, Romero-Yuste S, Ojeda-Garcia C, Moreno M, Bonilla G, Hernández-Rodriguez I, Lopez Corbeto M, Andréu Sánchez JL, Pérez Sandoval T, López Robles A, Carreira P, Mena-Vázquez N, Peralta-Ginés C, Urruticoechea-Arana A, Arboleya Rodríguez LM, Narváez J, Palma Sanchez D, Maiz-Alonso O, Fernández-Leroy J, Cabezas-Rodriguez I, Castellví I, Ruibal-Escribano A, De Dios-Jiménez Aberásturi J, Vela-Casasempere P, González-Montagut Gómez C, Blanco JM, Alvarez-Rivas N, Del-Val N, Rodíguez-Gómez M, Salgado-Pérez E, Fernández-López C, Cervantes Pérez EC, Devicente-Delmas A, Garcia-Magallon B, Hidalgo C, Fernández S, García-Fernández E, López-Sánchez R, Castro S, Morales-Garrido P, García-Valle A, Expósito R, Exposito-Perez L, Pérez Albaladejo L, García-Aparicio Á, Blanco R, González-Gay MA. SAT0075 ABATACEPT IN COMBINATION WITH METOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED TO INTERSTITIAL LUNG DISEASE: NATIONAL MULTICENTER STUDY OF 263 PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interstitial Lung Disease (ILD) is an extra-articular complication of rheumatoid arthritis (RA) that is associated with increased morbidity and mortality. Conventional disease-modifying drugs (DMARDs) such as methotrexate (MTX) have been implicated in the development and exacerbation of a pre-existing ILD.Objectives:The aim of our study was to check the influence of combined MTX treatment in patients with RA-ILD treated with abatacept (ABA).Methods:National multicentre retrospective registry of 263 patients with RA-ILD treated with ABA. RA was diagnosed according to the ACR classification criteria of 1987 or by the EULAR/ACR criteria of 2010. ILD was diagnosed by high resolution computed tomography (HRCT). In this study we have done a subanalysis of the 46 patients treated with ABA in combination with MTX (ABA+MTX) vs. 217 patients treated with ABA in monotherapy or in combination with other synthetic DMARDs. Efficacy was evaluated according to the following parameters: a) Dyspnoea (MMRC) considering variations ≥ 1; b) Lung function test (LFT) considering variations ≥ 10% in FVC and a variation of DLCO ≥ 10%; c) Imaging test (HRCT) d) DAS28 score e) prednisone dose. Variables were collected at the beginning of the study and at months 3, 6, 12 and then every 12 months until a maximum of 60 months.Results:263 patients with ILD associated with RA were included in the study with mean age 64.64±10 years. RF or CCPA were positive in 235 (89.4%) and 233 (88.6%) cases, respectively, with a mean follow-up of 22.7±19.7 months. Baseline characteristics of both groups are shown in table 1, while data obtained during evolution of this complication are presented in Figure 1.Conclusion:Despite the baseline differences of both groups, the good evolution in the ABA+MTX subgroup suggests that this therapeutic strategy can be a safe combination for patients with RA-ILD.ABA with MTX (n=46)ABA w/t MTX (n=217)PSex (F/M)28/18122/950.625Age (years)65.11±10.216.2±9.80.202RF/CCPA + (%)91.3/91.389.8/90.10.810Smoking or past smoking (%)47.855.10.417Follow-up (months)22.73±18.0022.3±20.850.916DAS28 at baseline4.08±1.514.61±1.470.056DAS28 at last visit3.00±1.463.13±1.310.642Prednisone at baseline, median (IQR) (mg)5 (5-7.5)7.75 (5-15)0.008*Prednisone at the end of study, median (IQR) (mg)5 (1-5)5 (5-7.5)0.032*DLCO at baseline (%)66.85±19.0465.43±18.210.823DLCO at the end of study (%)66.05±20.9565.17±19.720.831FVC at baseline (%)90.06±17.7785.40±21.560.164FVC at the end of study (%)90.58±15,4584.21±21.490.038*Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD
Collapse
|
3
|
Fernández-Díaz C, Castañeda S, Melero R, Loricera J, Ortiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, Rodriguéz-Muguruza S, Rodrigez-Garcia S, Castellanos-Moreira R, Almodovar R, Aguilera Cros C, Villa-Blanco I, Ordoñez S, Romero-Yuste S, Ojeda-Garcia C, Moreno M, Bonilla G, Hernández-Rodriguez I, Lopez Corbeto M, Andréu Sánchez JL, Pérez Sandoval T, López Robles A, Carreira P, Mena-Vázquez N, Peralta-Ginés C, Urruticoechea-Arana A, Arboleya Rodríguez LM, Narváez J, Palma Sanchez D, Maiz-Alonso O, Fernández-Leroy J, Cabezas-Rodriguez I, Castellví I, Ruibal-Escribano A, De Dios-Jiménez Aberásturi J, Vela-Casasempere P, González-Montagut Gómez C, Blanco JM, Alvarez-Rivas N, Del-Val N, Rodíguez-Gómez M, Salgado-Pérez E, Fernández-López C, Cervantes Pérez EC, Devicente-Delmas A, Garcia-Magallon B, Hidalgo C, Fernández S, López-Sánchez R, García-Fernández E, Castro S, Morales-Garrido P, García-Valle A, Expósito R, Exposito-Perez L, Pérez Albaladejo L, García-Aparicio Á, González-Gay MA, Blanco R. SAT0035 RESPONSE TO ABATACEPT OF DIFFERENT PATTERNS OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: NATIONAL MULTICENTER STUDY OF 263 PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1741] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA). In this line, several radiological patterns of RA-ILD have been described: i) usual interstitial pneumonia (UIP), ii) nonspecific interstitial pneumonia (NSIP), iii) obliterating bronchiolitis, iv) organized pneumonia and mixed patterns. Abatacept (ABA) could be an effective and safe option for patients with RA-ILD, although the response in the different radiological patterns is not well defined.Objectives:Our aim was to assess the response to ABA in different radiological patterns of ILD.Methods:Observational retrospective multicenter study of RA-ILD treated with ABA. ILD was diagnosed by HRCT and classified by radiological patterns in 3 different subgroups of RA-ILD: a) UIP, b) NSIP and c) “other”. ABA was used sc. or iv. at standard dose. We assessed: a) Dyspnoea (MMRC scale; significant variation ≥1); b) Respiratory function tests (significant changes ≥10% in FVC and DLCO); c) HRCT imaging; d) DAS28 e)prednisone dose.Variables were collected at months 0, 3, 6, 12 months and subsequently every 12 months until a maximum of 60 months.Results:We included 263 patients: 106 UIP, 84 NSIP and 73 others (150 women / 113 men), mean age 64.64±10 years. Total patients positive for RF or CCPA were 235 (89.4%) and 233 (88.6%), respectively. In 26 out of 263 patients, the development of ILD was closely related to the administration of sDMARDs (MTX n = 11 and LFN n = 1) or bDMARDs (ETN n = 5, ADA n = 4, CZP n = 2 and IFX n = 3). Patient characteristics are shown in table 1. Figure 1 shows the evolution of the cases with available data after a mean follow-up of 22.7±19.7 months. Mean DLCO and FVC remained stable in the 3 groups without statistically significant changes, and all the groups showed a statistically significant reduction in DAS28 and prednisone dose.Conclusion:ABA could be a good choice of treatment in patients with RA-ILD independently of the radiological pattern of ILD.Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, R. López-Sánchez: None declared, Edilia García-Fernández: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
Collapse
|
4
|
Fernández-Díaz C, Castañeda S, Melero R, Loricera J, Ortiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, Rodriguéz-Muguruza S, Rodrigez-Garcia S, Castellanos-Moreira R, Almodovar R, Aguilera Cros C, Villa-Blanco I, Ordoñez S, Romero-Yuste S, Ojeda-Garcia C, Moreno M, Bonilla G, Hernández-Rodriguez I, Lopez Corbeto M, Andréu Sánchez JL, Pérez Sandoval T, López Robles A, Carreira P, Mena-Vázquez N, Peralta-Ginés C, Urruticoechea-Arana A, Arboleya Rodríguez LM, Narváez J, Palma Sanchez D, Maiz-Alonso O, Fernández-Leroy J, Cabezas-Rodriguez I, Castellví I, Ruibal-Escribano A, De Dios-Jiménez Aberásturi J, Vela-Casasempere P, González-Montagut Gómez C, Blanco JM, Alvarez-Rivas N, Del-Val N, Rodíguez-Gómez M, Salgado-Pérez E, Fernández-López C, Cervantes Pérez EC, Devicente-Delmas A, Garcia-Magallon B, Hidalgo C, Fernández S, García-Fernández E, López-Sánchez R, Castro S, Morales-Garrido P, García-Valle A, Expósito R, Exposito-Perez L, Pérez Albaladejo L, García-Aparicio Á, González-Gay MA, Blanco R. OP0212 ABATACEPT IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 263 PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Interstitial Lung Disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Several conventional disease-modifying anti-rheumatic drugs (cDMARDs) and biologic (b) DMARDs may induce or impaired ILD-RA. Abatacept (ABA) may be useful in ILD-RA (1).Objectives:To assess the efficacy and safety of ABA in a large series of ILD-RA for a long-term follow-up.Methods:Multicenter open-level study of ILD-RA treated with at least 1 dose of ABA. ILD was diagnosed by high-resolution computed tomography (HRTC). We study these outcomes: a) 1-point change Modied Medical Research Council (MMRC); b) forced vital capacity (FVC) and/or DLCO improvement or decline ≥10%; c) change in HRCT, d) change in DAS28. e) Prednisone dose. Values were collected at 0, 3, 6, 12 and then every 12 months.Results:We studied 263 patients (150 women/113 men) (mean age;64.6±10 years), with ILD-RA. At ABA-onset they were smokers or exsmoker (53.8%), positive APCC (88.6%), median [IQR] duration of ILD of 12 [3-41.25] months, mean DLCO (65.7±18.3) and FVC (85.9±21.8).The ILD-pattern were usual interstitial pneumonia (UIP) (40.3%), non-specific interstitial pneumonia (NSIP) (31.9%) and others (27.8%).ABA was prescribed at standard subcutaneous (125 mg/w) in 196 (74.5%) or intravenously (10 mg/kg/4 w) in 67 (25.5%); in monotherapy (n=111) or combined with cDMARDs (n=152); especially leflunomide (n=55), MTX (n=46), or antimarials (n=21).After a mean follow-up of 22.7±19.7 months most outcomes remain stable (Figure). Moreover, DAS28 improved from 4.5±1.5 to 3.1±1.3; prednisone dose reduced from a median 7.5 [5-10] to 5 mg [5-7.5] and retention rate was 76.4%. The main adverse effects were serious infections (n=28), neoplasia (n=3), serious infusion reaction (n=1) and myocardial infarction (n=1).Conclusion:ABA seems effective and relatively safe in ILD-RA.References:[1]Fernández-Díaz C et al. Semin Arthritis Rheum. 2018; 48:22-27Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer.CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
Collapse
|
5
|
Linares F, García-Fernández E, López-Garzón FJ, Domingo-García M, Orte A, Rodríguez-Diéguez A, Galindo MA. Multifunctional behavior of molecules comprising stacked cytosine-Ag I-cytosine base pairs; towards conducting and photoluminescence silver-DNA nanowires. Chem Sci 2019; 10:1126-1137. [PMID: 30774910 PMCID: PMC6346629 DOI: 10.1039/c8sc04036b] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 11/04/2018] [Indexed: 12/20/2022] Open
Abstract
DNA molecules containing a 1D silver array may be applied for nanotechnology applications, but first their conducting and photoluminescence behavior must be enhanced. Here we have synthesized and characterized three new helical compounds based on stacked silver-mediated cytosine base pairs [Ag(mC)2]X (mC = N1-methylcytosine; X = NO3 (1), BF4 (2) and ClO4 (3)), that contain uninterrupted polymeric AgI chains that run through the center of the helixes, comparable to related silver-DNA structures. The exposure of nanostructures of [Ag(mC)2]BF4 (2) to cold hydrogen plasma stimulates the reduction of the prearranged AgI polymeric chains to metallic silver along the material. This solvent-free reduction strategy leads to the compound [AgI(mC)2]X@Ag0 (2H) that contains uniformly well-distributed silver metallic nanostructures that are responsible for the new conducting and photoluminescence properties of the material. The presence of silver nanostructures alongside compound 2H has been evaluated by means of X-ray photoelectron spectroscopy (XPS), UV-vis spectroscopy, and X-ray powder diffraction (XRPD). The conducting and photoactive properties of 2H were studied by electrostatic force microscopy (EFM) and conducting-AFM (c-AFM), and photoluminescence microscopy (PL), respectively. The results demonstrate that the presence of well-organized metallic silver nanoentities on the material is responsible for the novel conductivity and photoactive properties of the material. This methodology can be employed for the generation of multifunctional silver-DNA related materials with tailored properties.
Collapse
Affiliation(s)
- Fátima Linares
- Unidad de Microscopía de Fuerza Atómica , Centro de Instrumentación Científica , Universidad de Granada , Paseo Prof. Juan Osorio s/n , 18003 , Granada , Spain .
| | - Emilio García-Fernández
- Departamento de Fisicoquímica , Facultad de Farmacia , Universidad de Granada , Campus Cartuja , 18071 , Granada , Spain
| | - F Javier López-Garzón
- Departamento de Química Inorgánica , Facultad de Ciencias , Universidad de Granada , Avd. Fuentenueva s/n , 18071 , Granada , Spain .
| | - María Domingo-García
- Departamento de Química Inorgánica , Facultad de Ciencias , Universidad de Granada , Avd. Fuentenueva s/n , 18071 , Granada , Spain .
| | - Angel Orte
- Departamento de Fisicoquímica , Facultad de Farmacia , Universidad de Granada , Campus Cartuja , 18071 , Granada , Spain
| | - Antonio Rodríguez-Diéguez
- Departamento de Química Inorgánica , Facultad de Ciencias , Universidad de Granada , Avd. Fuentenueva s/n , 18071 , Granada , Spain .
| | - Miguel A Galindo
- Departamento de Química Inorgánica , Facultad de Ciencias , Universidad de Granada , Avd. Fuentenueva s/n , 18071 , Granada , Spain .
| |
Collapse
|
6
|
González-López G, Ceballos-Rodríguez R, García-Fernández E. Rapidly Growing Lesion on the Chest. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2018.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
7
|
González-López G, Ceballos-Rodríguez RM, García-Fernández E. Rapidly Growing Lesion on the Chest. Actas Dermosifiliogr (Engl Ed) 2018; 109:821-822. [PMID: 29395032 DOI: 10.1016/j.ad.2017.04.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 02/23/2017] [Accepted: 04/11/2017] [Indexed: 10/18/2022] Open
Affiliation(s)
- G González-López
- Servicio de Dermatología, Hospital Universitario La Paz, Madrid, España.
| | | | - E García-Fernández
- Servicio de Anatomía Patológica, Hospital Universitario La Paz, Madrid, España
| |
Collapse
|
8
|
Hidalgo-García Y, García-Fernández E, Palacio-Aller L, Gonzalvo P. Schnitzler Syndrome With Response to Anakinra Monotherapy: 7 Years of Follow-up. Actas Dermo-Sifiliográficas (English Edition) 2017. [DOI: 10.1016/j.adengl.2017.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Reiné P, Justicia J, Morcillo SP, Mazzeo G, García-Fernández E, Rodríguez-Diéguez A, Álvarez de Cienfuegos L, Abbate S, Cuerva JM, Longhi G, Miguel D. Exploring potentialities and limitations of stapledo-oligo(phenyleneethynylene)s (o-OPEs) as efficient circularly polarized luminescence emitters. Chirality 2017; 30:43-54. [DOI: 10.1002/chir.22774] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 09/21/2017] [Accepted: 09/22/2017] [Indexed: 12/25/2022]
Affiliation(s)
- Pablo Reiné
- Department of Organic Chemistry; University of Granada; Granada Spain
| | - José Justicia
- Department of Organic Chemistry; University of Granada; Granada Spain
| | - Sara P. Morcillo
- Department of Organic Chemistry; University of Granada; Granada Spain
| | - Giuseppe Mazzeo
- Dipartimento di Medicina Molecolare e Traslazionale; Universitá di Brescia; Brescia Italy
| | | | | | | | - Sergio Abbate
- Dipartimento di Medicina Molecolare e Traslazionale; Universitá di Brescia; Brescia Italy
| | - Juan M. Cuerva
- Department of Organic Chemistry; University of Granada; Granada Spain
| | - Giovanna Longhi
- Dipartimento di Medicina Molecolare e Traslazionale; Universitá di Brescia; Brescia Italy
| | - Delia Miguel
- Department of Physical Chemistry; University of Granada; Granada Spain
| |
Collapse
|
10
|
Carmona C, García-Fernández E, Hidalgo J, Sánchez-Coronilla A, Balón M. New Insights on the 7-azaindole Photophysics: The Overlooked Role of Its Non Phototautomerizable Hydrogen Bonded Complexes. J Fluoresc 2014; 24:45-55. [DOI: 10.1007/s10895-013-1267-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Accepted: 07/08/2013] [Indexed: 11/24/2022]
|
11
|
Alperi M, Belmonte-Serrano M, Lluch P, Trenor P, Calvo-Alen J, García-Fernández E, Olivé A, Tinture J, Romero A. FRI0195 Tocilizumab infusion performed in 31 minutes in patients with rheumatoid arthritis is safe and well tolerated. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
García-Fernández E, Carmona C, Muñoz MA, Hidalgo J, Balón M. Electronic spectra and photophysics of the α-carboline (1-azacarbazole) monomer. Spectrochim Acta A Mol Biomol Spectrosc 2011; 84:130-136. [PMID: 21968208 DOI: 10.1016/j.saa.2011.09.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 09/07/2011] [Accepted: 09/09/2011] [Indexed: 05/31/2023]
Abstract
The UV-vis electronic absorption and emission spectra of α-carboline or 1-azacarbazole, 9H-pyrido[2,3-b]indole, AC, have been investigated in aprotic solvents. Radiative, k(r), non-radiative, k(nr), rate constants and natural lifetimes, τ(N), of the AC monomer in hexane and acetonitrile, obtained from the experimentally determined fluorescence quantum yields and fluorescence lifetimes, have been compared with those theoretically estimated. The closeness between these experimental and theoretical data, the small Stokes shifts, the mirror image relationship between the absorption and fluorescence spectra and the close correspondence between the absorption and fluorescence excitation spectra, provide good evidences that the emission of AC monomer occurs directly from its lowest singlet excited state. The mono- and multi-parametric analyses of the AC solvatochromism indicate that the polarity-polarizability, the hydrogen bond donor and the hydrogen bond acceptor properties of the solvent preferentially stabilize the singlet excited over the ground state. These analyses also reveal that photoexcitation reinforces the hydrogen bond donor and acceptor properties of the AC, becoming the pyridinic nitrogen atom more basic and the pyrrolic group more acid.
Collapse
Affiliation(s)
- Emilio García-Fernández
- Departamento de Química Física, Facultad de Farmacia Universidad de Sevilla, 41012 Sevilla, Spain
| | | | | | | | | |
Collapse
|
13
|
García-Fernández E, Carmona C, Muñoz MA, Hidalgo J, Balón M. Spectral and photophysical properties of α-carboline (1-azacarbazole) in aqueous solutions. J Fluoresc 2011; 22:815-25. [PMID: 22147021 DOI: 10.1007/s10895-011-1016-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 11/21/2011] [Indexed: 11/26/2022]
Abstract
The absorption and fluorescence spectra of α-carboline, 9H-pyrido[2,3-b]indole, AC, in organic aprotic solvents containing different water proportions and in acid/base aqueous solutions inside and outside the pH range have been examined. In the organic aprotic solvents, the addition of increasing concentrations of water sequentially quenches and shifts to the red the fluorescence spectra of AC. These spectral changes have been rationalized assuming the formation, at the lower water concentrations, of a discrete ground state non-cyclic weakly fluorescent AC hydrate emitting at 376 nm that, upon increasing the water concentrations, evolves to a higher order AC poly hydrate emitting at 397 nm. The changes of the AC absorption spectra in aqueous acid/basic solutions indicate the existence of three ground state prototropic species; the pyridinic protonated cation, C (pK(a) = 4.10 ± 0.05), the neutral, N (pK(a) = 14.5 ± 0.2), and the pyrrolic deprotonated anion, A. Conversely, the changes of the AC fluorescence spectra in these media indicate the existence of four excited state species emitting at 376 nm, 397 nm, 460 nm and 465 nm. Since the emissions at 376 nm and 397 nm satisfactorily match those of the hydrates observed in the organic-water mixtures, they were consistently assigned to two differently hydrated ground state N species. The remaining emissions at 460 nm and 465 nm have been assigned without ambiguity, on the basis of their excitation spectra, to the C and A species, respectively. The excited-state pK(a)s of the prototropic species of AC have been estimated by using the Förster-Weller cycle.
Collapse
Affiliation(s)
- Emilio García-Fernández
- Departamento de Química Física, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
| | | | | | | | | |
Collapse
|
14
|
García-Fernández E, Carmona C, Muñoz MA, Hidalgo J, Balón M. A photophysical study of the α-carboline (1-azacarbazole) aggregation process. Photochem Photobiol 2011; 88:277-84. [PMID: 22145665 DOI: 10.1111/j.1751-1097.2011.01056.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This paper reports a comprehensive photophysical study of the aggregation process of 1-azacarbazole, or α-carboline (9H-pyrido[2,3-b]indole), AC, in low polar aprotic solvents by using absorption, steady state and time-resolved fluorescence spectroscopic techniques. To ascertain the characteristics of the aggregation process we have studied the changes produced by the increase of the AC concentration and the decrease of the temperature on the absorption and fluorescence spectra of the AC monomer. Previously, to aid the interpretation of these results, the hydrogen bonding interactions of the AC monomer with pyridine, PY, and indole, IND, have been also analyzed. The results obtained from these studies reveal that, under our experimental conditions, AC does not form doubly hydrogen bonded cyclic dimers, (AC)(2), but singly hydrogen bonded open dimers, AC-AC, and open higher aggregates, (-AC-)(n). The formation of these species shifts to the red the absorption spectrum of the AC monomer and quenches its fluorescence.
Collapse
Affiliation(s)
- Emilio García-Fernández
- Departamento de Química Física, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
| | | | | | | | | |
Collapse
|
15
|
Grueso E, Sanchez F, Martin V, García-Fernández E, Prado-Gotor R. Quantification of salts and cosolvents–DNA interactions in terms of free energies: A study using the pyren-1-carboxyaldehyde as fluorescent probe. Chem Phys 2008. [DOI: 10.1016/j.chemphys.2008.06.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Nistal M, García-Fernández E, Mariño-Enríquez A, Serrano A, Regadera J, González-Peramato P. Valor de la biopsia gonadal en el diagnóstico de los desórdenes del desarrollo sexual. Actas Urol Esp 2007. [DOI: 10.4321/s0210-48062007000900012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Nistal M, García-Fernández E, Mariño-Enríquez A, Serrano A, Regadera J, González-Peramato P. Valor de la biopsia gonadal en el diagnóstico de los desórdenes del desarrollo sexual. Actas Urol Esp 2007; 31:1056-75. [DOI: 10.1016/s0210-4806(07)73767-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Pascual I, Alvarez-Gallego M, Herreros MD, Garcia-Olmo D, García-Fernández E. Metastasis in anal mucosa from bladder cancer. Tech Coloproctol 2006; 10:255. [PMID: 17086663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
19
|
Jiménez R, García-Fernández E, Grueso E, Fernández I, Marín I, Sanz J, Torrado L, Villegas D, González L, Stürekow H, Leon M, Lería F, Machuca E, Martinez L, Morales J, Villa-Bernaldez I, Prado-Gotor R. A study of the non-electrostatic interaction micelle/charged ligand: A comparison of the results obtained by two different methods. Chem Phys Lett 2006. [DOI: 10.1016/j.cplett.2005.10.074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|